Clinical trials: Reflux
Eosinophilic Esophagitis
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
This trial will study three doses of reslizumab versus placebo in children with eosinophilic esophagitis (EE). The objectives of the trial will be to study the effectiveness of reslizumab in improving the clinical signs and…
- Trial name
- NCT00538434
- Testing
- Reslizumab, Saline
- Where
- 37 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Ception Therapeutics
Varicose Veins
The BRILLIANT Study
This trial was designed as a prospective, multi-center, randomized clinical trial of the FDA-cleared Vari-Lase Bright Tip Fiber compared to commercially available standard bare-tip laser fiber (control) to demonstrate the safety…
- Trial name
- BRILLIANT (NCT00618514)
- Testing
- Bright Tip Laser Fiber, Bare Tip Laser Fiber
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Vascular Solutions LLC
Esophagitis, Reflux, Esophagitis, Peptic
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00255151
- Testing
- Dexlansoprazole MR
- Where
- 100 sites in United States
- Volunteers
- 451 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease (GERD)
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.
- Trial name
- NCT06916130
- Testing
- AD-120A, AD-120
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Oesophageal Reflux, Gastric Reflux
Efficacy and Speed of Action of a Product to Control Gastric Hydration and Gastroesophageal Reflux
A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and…
- Conditions
- Oesophageal Reflux, Gastric Reflux, Hyperactivity; Stomach
- Trial name
- AQUAA (NCT05060744)
- Testing
- Antacid, Control
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Uriach Consumer Healthcare
Gastroesophageal Reflux, GERD
Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Conditions
- Gastroesophageal Reflux, GERD, GORD
- Trial name
- NCT00261339
- Testing
- Pantoprazole
- Where
- 45 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Takeda
GERD (Gastroesophageal Reflux Disease)
An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients
This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.
- Trial name
- NCT07678177
- Where
- South Korea
- Volunteers
- 5,384 people
- Sponsor
- HK inno.N Corporation
Tricuspid Regurgitation
Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™
The TriCinch System™ is intended for percutaneous treatment of tricuspid regurgitation. It is a percutaneous catheter-based device designed for tricuspid valve repair in order to decrease effective cross-sectional area and…
- Trial name
- PREVENT (NCT02098200)
- Testing
- TriCinch System
- Where
- 14 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- 4Tech Cardio Ltd.
Gastroesophageal Reflux Disease
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251745
- Testing
- Dexlansoprazole MR
- Where
- 95 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Chest Pain, Gastroesophageal Reflux
Chest Pain Pilot Study
The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.
- Trial name
- NCT00251901
- Testing
- Esomeprazole
- Where
- 80 sites in Canada, Denmark and 4 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
GERD
Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease
The purpose of this prospective, multicenter study was to evaluate the safety and efficacy of endoscopic full-thickness plication for the treatment of symptomatic gastroesophageal reflux.
- Trial name
- NCT00587522
- Testing
- NDO Full-thickness Plicator
- Where
- 7 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- NDO Surgical, Inc.
Indigestion, Dyspepsia
A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms
The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux…
- Conditions
- Indigestion, Dyspepsia, Bloating, Loss of Appetite
- Trial name
- NCT06755671
- Testing
- Danning Tablet
- Where
- China
- Volunteers
- 4,500 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Non-erosive Gastroesophageal Reflux Disease
Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease
The purpose of this study is to investigate the superiority of efficacy of TAK-438, once daily (QD), to placebo in patients with non-erosive gastroesophageal reflux disease.
- Trial name
- NCT01474369
- Testing
- TAK-438
- Where
- 52 sites in Japan
- Volunteers
- 827 people
- Sponsor
- Takeda
Mitral Valve Regurgitation
Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation
The purpose of this study is to test the safety and device performance of the Mitralign system ("MPAS") to treat functional mitral valve regurgitation.
- Trial name
- ALIGN (NCT01740583)
- Testing
- percutaneous annuloplasty
- Where
- 8 sites in Colombia, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Mitralign, Inc.
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to compare the efficacy of rabeprazole extended release (ER) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive…
- Trial name
- NCT00838526
- Testing
- Rabeprazole ER, Ranitidine
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
GERD (Gastroesophageal Reflux Disease)
Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms
The purpose of this research is to evaluate the safety and effectiveness of the eGERD device, which is a novel device for treating Gastroesophageal Reflux Disease (GERD). The main questions this research aims to answer are: 1.
- Trial name
- NCT06613438
- Testing
- eGERD device
- Where
- 5 sites in United States, Israel
- Volunteers
- 84 people
- Sponsor
- Gerd Care Medical Ltd
GERD
EndoStim Patient Registry
To provide a research tool enabling physicians to monitor long term clinical outcomes for patients undergoing gastroesophageal reflux disease (GERD) treatment with EndoStim LES Stimulation System.
- Trial name
- RESTORE (NCT02441400)
- Testing
- EndoStim LES Stimulation System
- Where
- 30 sites in Argentina, Austria and 5 more
- Volunteers
- 350 people
- Sponsor
- EndoStim Inc.
Gastro-esophageal Reflux Disease (GERD)
Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients
Multi-centre, randomised, open-label, placebo-controlled, two-period crossover study of 4 hour pH monitoring following a refluxogenic meal and drink.
- Trial name
- NCT02619747
- Testing
- Compound Sodium Alginate Oral Suspension sachet
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Chronic Posterior Laryngitis (CPL)
Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux
This study looks at how effective acid suppression therapy is on symptoms associated with chronic posterior laryngitis (CPL) in patients with documented pharyngeal acid reflux.
- Trial name
- NCT00628667
- Testing
- Esomeprazole
- Volunteers
- 120 people
- Sponsor
- AstraZeneca